clobazam Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diazepam derivatives 682 22316-47-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clobazam
  • clobazepam
  • frisium
  • frizium
  • urbadan
A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.
  • Molecular weight: 300.74
  • Formula: C16H13ClN2O2
  • CLOGP: 2.44
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 40.62
  • ALOGS: -3.26
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.19 mg/mL Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 90 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Oct. 21, 2011 FDA LUNDBECK LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seizure 1416.65 19.10 710 13832 122344 46549176
Epilepsy 569.71 19.10 230 14312 23508 46648012
Status epilepticus 544.35 19.10 193 14349 13786 46657734
Drug withdrawal convulsions 394.25 19.10 90 14452 1251 46670269
Psychogenic seizure 370.77 19.10 84 14458 1126 46670394
Somnolence 225.51 19.10 260 14282 156261 46515259
Multiple-drug resistance 208.73 19.10 62 14480 2503 46669017
Drug interaction 192.45 19.10 274 14268 202820 46468700
Generalised tonic-clonic seizure 163.34 19.10 103 14439 27019 46644501
Partial seizures 153.36 19.10 58 14484 4952 46666568
Paradoxical drug reaction 124.39 19.10 41 14501 2335 46669185
Aggression 123.63 19.10 81 14461 22663 46648857
Drug ineffective 114.73 19.10 464 14078 677374 45994146
Drug resistance 112.22 19.10 69 14473 17299 46654221
Foetal exposure during pregnancy 108.17 19.10 84 14458 30663 46640857
Petit mal epilepsy 93.95 19.10 36 14506 3184 46668336
Respiratory disorder neonatal 86.81 19.10 25 14517 903 46670617
Drug reaction with eosinophilia and systemic symptoms 85.45 19.10 72 14470 29476 46642044
Abnormal behaviour 83.93 19.10 62 14480 20996 46650524
Propofol infusion syndrome 81.89 19.10 23 14519 758 46670762
Mitochondrial DNULL mutation 79.99 19.10 18 14524 233 46671287
Irritability 76.51 19.10 67 14475 28879 46642641
Bradycardia neonatal 73.01 19.10 20 14522 600 46670920
Ataxia 71.78 19.10 48 14494 13882 46657638
Off label use 70.22 19.10 268 14274 379573 46291947
Drug level decreased 64.11 19.10 33 14509 5879 46665641
Selective eating disorder 63.70 19.10 23 14519 1722 46669798
Pain 63.41 19.10 35 14507 476913 46194607
Rheumatoid arthritis 62.35 19.10 3 14539 240212 46431308
Tonic convulsion 61.59 19.10 20 14522 1086 46670434
Nausea 61.12 19.10 75 14467 687379 45984141
Weight gain poor 60.97 19.10 18 14524 710 46670810
Gene mutation 57.99 19.10 19 14523 1061 46670459
Exposure during pregnancy 57.62 19.10 113 14429 108099 46563421
Diarrhoea 57.53 19.10 54 14488 559548 46111972
Hyperammonaemia 56.03 19.10 28 14514 4688 46666832
Aura 55.36 19.10 18 14524 981 46670539
Focal dyscognitive seizures 52.93 19.10 23 14519 2805 46668715
Pregnancy 52.82 19.10 53 14489 27084 46644436
Arthralgia 52.54 19.10 24 14518 364579 46306941
Psychomotor skills impaired 51.70 19.10 21 14521 2165 46669355
Sedation 50.68 19.10 48 14494 22862 46648658
Atonic seizures 50.49 19.10 15 14527 605 46670915
Developmental delay 48.53 19.10 17 14525 1165 46670355
Premature baby 48.00 19.10 42 14500 18070 46653450
Seizure cluster 47.31 19.10 11 14531 166 46671354
Lymphangioleiomyomatosis 47.25 19.10 11 14531 167 46671353
Drug dependence 46.53 19.10 43 14499 19858 46651662
Exposure via breast milk 46.30 19.10 17 14525 1335 46670185
Dyspnoea 45.97 19.10 56 14486 515492 46156028
Angiofibroma 45.85 19.10 10 14532 111 46671409
Blood gases abnormal 45.77 19.10 14 14528 624 46670896
Anticonvulsant drug level increased 45.48 19.10 17 14525 1403 46670117
Drug level increased 45.37 19.10 41 14501 18400 46653120
Maternal exposure during pregnancy 45.09 19.10 99 14443 102450 46569070
Disturbance in attention 44.51 19.10 52 14490 31508 46640012
Low birth weight baby 44.03 19.10 25 14517 5409 46666111
Drug hypersensitivity 41.95 19.10 12 14530 243813 46427707
Hypotonia 41.53 19.10 28 14514 8201 46663319
Electroencephalogram abnormal 40.83 19.10 21 14521 3733 46667787
Angiomyolipoma 40.56 19.10 10 14532 196 46671324
Hyperammonaemic encephalopathy 39.99 19.10 17 14525 1965 46669555
Systolic dysfunction 39.44 19.10 15 14527 1299 46670221
Depressed mood 39.05 19.10 50 14492 33269 46638251
Overdose 38.80 19.10 93 14449 101886 46569634
Joint swelling 37.57 19.10 4 14538 166069 46505451
Sudden unexplained death in epilepsy 37.20 19.10 10 14532 279 46671241
Suicidal behaviour 36.55 19.10 17 14525 2431 46669089
Fanconi syndrome 36.34 19.10 13 14529 947 46670573
Unmasking of previously unidentified disease 35.81 19.10 12 14530 719 46670801
Psychotic disorder 34.81 19.10 39 14503 22582 46648938
Temporal lobe epilepsy 34.41 19.10 10 14532 373 46671147
Cholestasis of pregnancy 34.34 19.10 13 14529 1111 46670409
Intentional product misuse 33.72 19.10 56 14486 47072 46624448
Abdominal discomfort 33.29 19.10 4 14538 151161 46520359
Coma blister 32.93 19.10 8 14534 147 46671373
Mood altered 32.15 19.10 29 14513 12978 46658542
Hepatocellular injury 31.03 19.10 42 14500 29480 46642040
Condition aggravated 30.63 19.10 154 14388 244898 46426622
Balance disorder 30.30 19.10 64 14478 64457 46607063
Pain in extremity 30.13 19.10 22 14520 258658 46412862
Brown tumour 29.74 19.10 6 14536 44 46671476
Anticonvulsant drug level decreased 29.59 19.10 12 14530 1232 46670288
Electrocardiogram repolarisation abnormality 29.39 19.10 12 14530 1253 46670267
Infantile spasms 28.74 19.10 8 14534 255 46671265
Apnoea 27.87 19.10 21 14521 7318 46664202
Hypopnoea 27.62 19.10 14 14528 2414 46669106
Therapeutic product effective for unapproved indication 27.08 19.10 6 14536 72 46671448
Benzodiazepine drug level increased 26.47 19.10 7 14535 183 46671337
Neurosurgery 26.42 19.10 5 14537 25 46671495
Excessive eye blinking 26.13 19.10 9 14533 586 46670934
Polychromasia 26.10 19.10 6 14536 86 46671434
Congenital central nervous system anomaly 26.08 19.10 8 14534 360 46671160
Therapeutic product ineffective for unapproved indication 25.84 19.10 7 14535 201 46671319
Stevens-Johnson syndrome 25.79 19.10 34 14508 23263 46648257
Electrocardiogram ST segment elevation 24.67 19.10 15 14527 3680 46667840
Brain operation 24.64 19.10 8 14534 434 46671086
Hallucination, visual 24.45 19.10 29 14513 17844 46653676
Coma 24.12 19.10 55 14487 58294 46613226
Hypothermia 24.08 19.10 24 14518 12159 46659361
Pregnancy on contraceptive 24.02 19.10 10 14532 1097 46670423
Intentional overdose 23.37 19.10 58 14484 64886 46606634
Speech disorder 23.26 19.10 41 14501 36126 46635394
Drug ineffective for unapproved indication 23.06 19.10 27 14515 16386 46655134
Encephalopathy 22.81 19.10 39 14503 33550 46637970
Diplopia 22.54 19.10 29 14513 19376 46652144
Developmental regression 22.29 19.10 4 14538 14 46671506
Poisoning deliberate 22.25 19.10 19 14523 7907 46663613
Gingival hypertrophy 21.57 19.10 10 14532 1419 46670101
Cough 21.53 19.10 24 14518 230225 46441295
Abdominal pain 21.48 19.10 24 14518 230007 46441513
Cognitive disorder 21.42 19.10 40 14502 36843 46634677
Behaviour disorder 21.41 19.10 11 14531 1950 46669570
Drooling 21.36 19.10 13 14529 3196 46668324
Ventricular septal defect 21.01 19.10 14 14528 4020 46667500
Drop attacks 20.92 19.10 8 14534 703 46670817
Myoclonus 20.82 19.10 24 14518 14328 46657192
Peripheral swelling 20.34 19.10 12 14530 158059 46513461
Abortion spontaneous 20.14 19.10 43 14499 43603 46627917
Congenital tracheomalacia 19.87 19.10 4 14538 29 46671491
Asphyxia 19.69 19.10 15 14527 5311 46666209
Change in seizure presentation 19.65 19.10 6 14536 266 46671254
Premature delivery 19.64 19.10 29 14513 22040 46649480
Epileptic psychosis 19.63 19.10 4 14538 31 46671489
Monocyte count decreased 19.60 19.10 10 14532 1747 46669773
Calcinosis 19.54 19.10 10 14532 1759 46669761
Hypersomnia 19.40 19.10 24 14518 15415 46656105
Glioblastoma multiforme 19.30 19.10 8 14534 868 46670652
Infusion related reaction 19.29 19.10 4 14538 101204 46570316
Pneumonia aspiration 19.26 19.10 35 14507 31570 46639950

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seizure 1271.95 19.03 675 11820 97800 29842183
Status epilepticus 423.50 19.03 163 12332 10909 29929074
Epilepsy 320.59 19.03 160 12335 20009 29919974
Drug withdrawal convulsions 283.93 19.03 71 12424 1088 29938895
Somnolence 268.50 19.03 261 12234 96502 29843481
Generalised tonic-clonic seizure 169.27 19.03 104 12391 19447 29920536
Aggression 144.31 19.03 121 12374 36786 29903197
Foetal exposure during pregnancy 130.12 19.03 114 12381 36757 29903226
Abnormal behaviour 112.70 19.03 90 12405 25533 29914450
Drug ineffective 111.35 19.03 352 12143 340035 29599948
Partial seizures 110.98 19.03 46 12449 3721 29936262
Multiple-drug resistance 107.69 19.03 42 12453 2899 29937084
Sudden unexplained death in epilepsy 107.37 19.03 27 12468 423 29939560
Drug reaction with eosinophilia and systemic symptoms 88.47 19.03 82 12413 28406 29911577
Drug resistance 86.98 19.03 70 12425 20063 29919920
Sedation 86.16 19.03 64 12431 16309 29923674
Hypotonia 84.14 19.03 46 12449 6902 29933081
Psychogenic seizure 81.82 19.03 20 12475 277 29939706
Atonic seizures 81.53 19.03 18 12477 154 29939829
Petit mal epilepsy 80.45 19.03 33 12462 2598 29937385
Cognitive disorder 79.04 19.03 71 12424 23619 29916364
Anticonvulsant drug level increased 75.04 19.03 27 12468 1488 29938495
Hamartoma 69.21 19.03 13 12482 43 29939940
Encephalopathy 65.84 19.03 74 12421 32131 29907852
Ataxia 65.27 19.03 47 12448 11415 29928568
Behaviour disorder 59.58 19.03 26 12469 2386 29937597
Motor developmental delay 59.53 19.03 16 12479 329 29939654
Drug interaction 57.33 19.03 198 12297 199370 29740613
Dysmorphism 57.28 19.03 24 12471 1993 29937990
Fanconi syndrome 53.37 19.03 22 12473 1753 29938230
Developmental delay 52.63 19.03 23 12472 2118 29937865
Hyperammonaemic encephalopathy 52.56 19.03 22 12473 1822 29938161
Hyperammonaemia 51.93 19.03 31 12464 5489 29934494
Dyspnoea 49.60 19.03 40 12455 333255 29606728
Focal dyscognitive seizures 48.94 19.03 19 12476 1294 29938689
Autism spectrum disorder 48.78 19.03 19 12476 1306 29938677
Cerebral artery thrombosis 48.74 19.03 15 12480 506 29939477
Nystagmus 47.81 19.03 27 12468 4311 29935672
Psychomotor skills impaired 47.80 19.03 21 12474 1958 29938025
Intellectual disability 45.54 19.03 16 12479 822 29939161
Disturbance in attention 45.47 19.03 51 12444 22078 29917905
Brain scan abnormal 45.41 19.03 15 12480 638 29939345
Psychomotor retardation 44.10 19.03 21 12474 2358 29937625
Learning disorder 41.57 19.03 13 12482 463 29939520
Developmental regression 41.40 19.03 8 12487 32 29939951
Acute kidney injury 40.52 19.03 33 12462 273809 29666174
Speech disorder developmental 40.22 19.03 16 12479 1163 29938820
Respiratory depression 39.38 19.03 35 12460 11468 29928515
Drop attacks 39.15 19.03 13 12482 562 29939421
Language disorder 38.85 19.03 16 12479 1272 29938711
Salivary hypersecretion 38.50 19.03 29 12466 7537 29932446
Infantile spasms 38.40 19.03 11 12484 288 29939695
Atrial septal defect 37.05 19.03 27 12468 6674 29933309
Depressed level of consciousness 36.87 19.03 61 12434 38161 29901822
Diarrhoea 35.43 19.03 53 12442 334050 29605933
Foetal anticonvulsant syndrome 35.37 19.03 13 12482 761 29939222
Chest pain 35.12 19.03 4 12491 117623 29822360
Ehlers-Danlos syndrome 34.95 19.03 7 12488 35 29939948
Benzodiazepine drug level decreased 34.95 19.03 7 12488 35 29939948
Cerebellar atrophy 34.34 19.03 11 12484 424 29939559
Victim of child abuse 34.27 19.03 10 12485 280 29939703
Renal tubular acidosis 33.52 19.03 16 12479 1806 29938177
Areflexia 32.91 19.03 18 12477 2701 29937282
Therapeutic product effect incomplete 32.64 19.03 54 12441 33780 29906203
Irritability 32.58 19.03 44 12451 23006 29916977
Hepatocellular injury 32.08 19.03 46 12449 25425 29914558
Myocardial infarction 31.40 19.03 7 12488 125618 29814365
Product use issue 31.14 19.03 63 12432 45953 29894030
Febrile neutropenia 30.94 19.03 4 12491 106689 29833294
Anaemia 30.81 19.03 25 12470 207967 29732016
Pain 30.60 19.03 17 12478 172624 29767359
Intensive care unit acquired weakness 30.32 19.03 12 12483 860 29939123
Neonatal respiratory depression 30.32 19.03 10 12485 423 29939560
Stevens-Johnson syndrome 30.29 19.03 37 12458 17519 29922464
Hyperchloraemia 29.69 19.03 10 12485 452 29939531
Electroencephalogram abnormal 29.52 19.03 16 12479 2358 29937625
Maternal exposure during pregnancy 29.47 19.03 19 12476 3852 29936131
Product substitution issue 29.42 19.03 28 12467 10007 29929976
Death 28.75 19.03 67 12428 357216 29582767
Hypotonia neonatal 28.40 19.03 12 12483 1017 29938966
Condition aggravated 28.19 19.03 123 12372 137743 29802240
Psychomotor hyperactivity 28.10 19.03 25 12470 8199 29931784
Nausea 27.83 19.03 51 12444 296906 29643077
Drug dependence 27.62 19.03 39 12456 21256 29918727
Partial seizures with secondary generalisation 27.52 19.03 8 12487 221 29939762
Myoclonic epilepsy 27.45 19.03 11 12484 815 29939168
Circadian rhythm sleep disorder 27.42 19.03 9 12486 375 29939608
Seizure cluster 27.24 19.03 7 12488 120 29939863
Retrognathia 27.15 19.03 8 12487 232 29939751
Change in seizure presentation 27.00 19.03 6 12489 53 29939930
Hypothermia 26.74 19.03 26 12469 9541 29930442
Irregular sleep phase 25.65 19.03 6 12489 68 29939915
Hypospadias 25.08 19.03 15 12480 2664 29937319
Pneumonia aspiration 24.70 19.03 51 12444 37729 29902254
Body dysmorphic disorder 24.55 19.03 6 12489 83 29939900
Haemophagocytic lymphohistiocytosis 24.39 19.03 25 12470 9766 29930217
Pain in extremity 24.05 19.03 8 12487 110213 29829770
Dysgraphia 23.84 19.03 12 12483 1519 29938464
Tonic convulsion 23.72 19.03 10 12485 843 29939140
Child abuse 23.40 19.03 7 12488 214 29939769
Reaction to excipient 23.21 19.03 8 12487 388 29939595
Developmental coordination disorder 23.17 19.03 5 12490 38 29939945
Arthralgia 23.15 19.03 14 12481 135777 29804206
Dystonia 22.73 19.03 24 12471 9703 29930280
Low set ears 22.66 19.03 8 12487 417 29939566
Premature baby 22.28 19.03 31 12464 16660 29923323
Cardiac failure 22.18 19.03 4 12491 83414 29856569
Hypernatraemia 22.16 19.03 21 12474 7463 29932520
Respiratory distress 22.13 19.03 45 12450 32927 29907056
Bronchiolitis 21.10 19.03 13 12482 2435 29937548
Haemoglobin decreased 20.54 19.03 11 12484 114087 29825896
Wrist deformity 20.40 19.03 7 12488 335 29939648
Patent ductus arteriosus 20.37 19.03 14 12481 3155 29936828
Cerebellar syndrome 20.33 19.03 12 12483 2080 29937903
Limb reduction defect 20.14 19.03 6 12489 181 29939802
Aphasia 20.06 19.03 32 12463 19407 29920576
Fatigue 19.94 19.03 68 12427 320605 29619378
Withdrawal syndrome 19.88 19.03 24 12471 11226 29928757
Lethargy 19.82 19.03 48 12447 39471 29900512
Dysarthria 19.74 19.03 41 12454 30449 29909534
Myoclonus 19.71 19.03 26 12469 13286 29926697
Poor feeding infant 19.66 19.03 7 12488 374 29939609
Gait disturbance 19.49 19.03 72 12423 74705 29865278
Otitis media acute 19.45 19.03 7 12488 386 29939597
Floppy infant 19.33 19.03 5 12490 88 29939895

Pharmacologic Action:

SourceCodeDescription
ATC N05BA09 NERVOUS SYSTEM
PSYCHOLEPTICS
ANXIOLYTICS
Benzodiazepine derivatives
FDA CS M0002356 Benzodiazepines
FDA EPC N0000175694 Benzodiazepine
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D000927 Anticonvulsants
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018682 GABA Agents
MeSH PA D018755 GABA Agonists
MeSH PA D058785 GABA-A Receptor Agonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
FDA MoA N0000182137 Cytochrome P450 2D6 Inhibitors
FDA MoA N0000185506 Cytochrome P450 3A4 Inducers
CHEBI has role CHEBI:35474 minor tranquilisers
CHEBI has role CHEBI:35623 antiepileptic
CHEBI has role CHEBI:50268 gaba modulators

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Lennox-Gastaut syndrome indication 230418006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.14 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL

External reference:

IDSource
4025788 VUID
N0000179086 NUI
D01253 KEGG_DRUG
4025788 VANDF
C0055891 UMLSCUI
CHEBI:31413 CHEBI
CHEMBL70418 ChEMBL_ID
DB00349 DRUGBANK_ID
D000078306 MESH_DESCRIPTOR_UI
2789 PUBCHEM_CID
7149 IUPHAR_LIGAND_ID
3055 INN_ID
2MRO291B4U UNII
151794 RXNORM
14923 MMSL
66309 MMSL
d04557 MMSL
003693 NDDF
387572002 SNOMEDCT_US
96236000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 0054-0526 TABLET 10 mg ORAL ANDA 31 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 0054-0527 TABLET 20 mg ORAL ANDA 31 sections
clobazam HUMAN PRESCRIPTION DRUG LABEL 1 0054-0561 SOLUTION 2.50 mg ORAL ANDA 32 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 0378-8043 SUSPENSION 2.50 mg ORAL ANDA 35 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 0527-1681 TABLET 10 mg ORAL ANDA 32 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 0527-1682 TABLET 20 mg ORAL ANDA 32 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 0527-5301 SUSPENSION 2.50 mg ORAL ANDA 33 sections
Clobazam Human Prescription Drug Label 1 0781-8013 TABLET 10 mg ORAL ANDA 32 sections
Clobazam Human Prescription Drug Label 1 0781-8014 TABLET 20 mg ORAL ANDA 32 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 0832-0580 TABLET 10 mg ORAL ANDA 39 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 0832-0581 TABLET 20 mg ORAL ANDA 39 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 0832-0585 SUSPENSION 2.50 mg ORAL ANDA 40 sections
SYMPAZAN HUMAN PRESCRIPTION DRUG LABEL 1 10094-205 FILM 5 mg ORAL NDA 35 sections
SYMPAZAN HUMAN PRESCRIPTION DRUG LABEL 1 10094-210 FILM 10 mg ORAL NDA 35 sections
SYMPAZAN HUMAN PRESCRIPTION DRUG LABEL 1 10094-220 FILM 20 mg ORAL NDA 35 sections
Clobazam Human Prescription Drug Label 1 16714-087 SUSPENSION 2.50 mg ORAL ANDA 34 sections
Clobazam Human Prescription Drug Label 1 16714-887 TABLET 10 mg ORAL ANDA 31 sections
Clobazam Human Prescription Drug Label 1 16714-888 TABLET 20 mg ORAL ANDA 31 sections
CLOBAZAM HUMAN PRESCRIPTION DRUG LABEL 1 16729-445 TABLET 10 mg ORAL ANDA 32 sections
CLOBAZAM HUMAN PRESCRIPTION DRUG LABEL 1 16729-446 TABLET 20 mg ORAL ANDA 32 sections
Clobazam Human Prescription Drug Label 1 31722-639 TABLET 10 mg ORAL ANDA 31 sections
Clobazam Human Prescription Drug Label 1 31722-640 TABLET 20 mg ORAL ANDA 31 sections
Clobazam Human Prescription Drug Label 1 31722-641 SUSPENSION 2.50 mg ORAL ANDA 34 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 42571-315 TABLET 10 mg ORAL ANDA 33 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 42571-316 TABLET 20 mg ORAL ANDA 33 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 51672-4202 TABLET 10 mg ORAL ANDA 33 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 51672-4203 TABLET 20 mg ORAL ANDA 33 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 51672-4210 SUSPENSION 2.50 mg ORAL ANDA 35 sections
clobazam HUMAN PRESCRIPTION DRUG LABEL 1 51991-900 TABLET 10 mg ORAL ANDA 39 sections
clobazam HUMAN PRESCRIPTION DRUG LABEL 1 51991-901 TABLET 20 mg ORAL ANDA 39 sections